Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...

A RECENT population-based analysis has highlighted potential behavioural side effects associated with Glucagon-like peptide 1 ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

A serial entrepreneur and a promising drug emerge from failed companies to pursue subsets of obesity patients, with or ...

Josh Gad reveled anxieties over his career after recently losing 40 pounds with the help of a weight loss medication.

Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and ...

An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the ...

HCR-188, a clinic-ready antibody, entering first-in-human clinical studies with top-line data anticipated in the second half ...